Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis

David A. Palma, Suresh Senan, Kayoko Tsujino, Robert B. Barriger, Ramesh Rengan, Marta Moreno, Jeffrey D. Bradley, Tae Hyun Kim, Sara Ramella, Lawrence B. Marks, Luigi De Petris, Larry Stitt, George Rodrigues

    Research output: Contribution to journalArticlepeer-review

    525 Scopus citations

    Abstract

    Background: Radiation pneumonitis is a dose-limiting toxicity for patients undergoing concurrent chemoradiation therapy (CCRT) for non-small cell lung cancer (NSCLC). We performed an individual patient data meta-analysis to determine factors predictive of clinically significant pneumonitis. Methods and Materials: After a systematic review of the literature, data were obtained on 836 patients who underwent CCRT in Europe, North America, and Asia. Patients were randomly divided into training and validation sets (two-thirds vs one-third of patients). Factors predictive of symptomatic pneumonitis (grade ≥2 by 1 of several scoring systems) or fatal pneumonitis were evaluated using logistic regression. Recursive partitioning analysis (RPA) was used to define risk groups. Results: The median radiation therapy dose was 60 Gy, and the median follow-up time was 2.3 years. Most patients received concurrent cisplatin/etoposide (38%) or carboplatin/paclitaxel (26%). The overall rate of symptomatic pneumonitis was 29.8% (n=249), with fatal pneumonitis in 1.9% (n=16). In the training set, factors predictive of symptomatic pneumonitis were lung volume receiving ≥20 Gy (V20) (odds ratio [OR] 1.03 per 1% increase, P=.008), and carboplatin/paclitaxel chemotherapy (OR 3.33, P<.001), with a trend for age (OR 1.24 per decade, P=.09); the model remained predictive in the validation set with good discrimination in both datasets (c-statistic >0.65). On RPA, the highest risk of pneumonitis (>50%) was in patients >65 years of age receiving carboplatin/paclitaxel. Predictors of fatal pneumonitis were daily dose >2 Gy, V20, and lower-lobe tumor location. Conclusions: Several treatment-related risk factors predict the development of symptomatic pneumonitis, and elderly patients who undergo CCRT with carboplatin-paclitaxel chemotherapy are at highest risk. Fatal pneumonitis, although uncommon, is related to dosimetric factors and tumor location.

    Original languageEnglish
    Pages (from-to)444-450
    Number of pages7
    JournalInternational Journal of Radiation Oncology Biology Physics
    Volume85
    Issue number2
    DOIs
    StatePublished - Feb 1 2013

    Fingerprint

    Dive into the research topics of 'Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis'. Together they form a unique fingerprint.

    Cite this